Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Freiburghaus, Catja; Emruli, Venera Kuci; Johansson, Angelica; Eskelund, Christian Winther; Grønbæk, Kirsten; Olsson, Roger; Ek, Fredrik; Jerkeman, Mats; Ek, Sara

doi:10.1186/s12885-018-4346-1

BMC Cancer

Article metrics
Last updated: Fri, 26 Apr 2024 3:43:52 Z

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Access & Citations

2148

Article Accesses
5

Web of Science
4

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com